{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:40:28Z","timestamp":1777333228874,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conflicting results have been reported on the impact of tenofovir versus entecavir on liver\u2010related outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To explore trends in clinical outcomes in chronic hepatitis B virus (HBV)\u2013infected patients and compare the impact of tenofovir versus entecavir on the risk of hepatocellular carcinoma (HCC), liver transplantation (LT) and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the French National Health Insurance Databases (SNDS) to identify HBV\u2010infected patients. We quantified the excess clinical burden from 2012 to 2021 by comparing the HBV\u2010infected cohort with a general population cohort, using 1:1 exact matching on birth date, sex, social deprivation index and follow\u2010up start date. The risks of mortality, HCC and LT were compared between patients treated with tenofovir and entecavir using inverse probability weighting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 101,740 patients were matched to the general population. From 2012 to 2021, the average annual decreases in excess mortality, incidence of HCC and LT were 3.7%, 8.0% and 11.9%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      for trend &lt;\u20090.001). During the same period, the nucleos(t)ide analog (NUC) treatment coverage significantly increased, particularly after 2016 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Among 14,054 treatment\u2010na\u00efve patients starting tenofovir (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097426) or entecavir (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096628), we observed no difference in the composite outcome of mortality, LT or HCC (HR, 1.09; 95% CI, 0.95\u20131.24). Tenofovir was associated with an increased risk of HCC compared with entecavir (HR, 1.31; 95% CI, 1.07\u20131.62).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tenofovir was associated with a higher risk of HCC compared with entecavir, although no difference in the composite outcome of mortality or liver\u2010related events was observed between the two treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.18462","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T06:44:57Z","timestamp":1735627497000},"page":"865-875","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10\u2010Year French Nationwide Cohort Study"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-9604","authenticated-orcid":false,"given":"Laurent","family":"Lam","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology H\u00f4pital Saint Joseph &amp; INSERM, UMR 1252 IRD SESSTIM, Aix Marseille Universit\u00e9  Marseille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-9591","authenticated-orcid":false,"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[{"name":"AP\u2010HP, Centre Universit\u00e9 Paris Centre, Groupe Hospitalier Cochin Port Royal, DMU Canc\u00e9rologie et sp\u00e9cialit\u00e9s m\u00e9dico\u2010chirurgicales, Service des Maladies du Foie &amp; Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, IPLESP  Paris France"},{"name":"Sorbonne Universit\u00e9, Department of Public Health, Assistance Publique\u2010H\u00f4pitaux de Paris, H\u00f4pital Saint\u2010Antoine  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801644"},{"key":"e_1_2_11_4_1","volume-title":"Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021: Accountability for the Global Health Sector Strategies 2016\u20132021: Actions for Impact","author":"World Health Organization","year":"2021"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.056"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.11.011"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01042.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00124-8"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00386-7"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30249-1"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4070"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16197"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13788"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32111-1"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-33"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23-2718"},{"issue":"21","key":"e_1_2_11_22_1","article-title":"Surveillance and Epidemiology of Hepatitis B and C in Europe \u2013 a Review","volume":"13","author":"Rantala M.","year":"2008","journal-title":"Euro Surveillance"},{"key":"e_1_2_11_23_1","volume-title":"Global Health Sector Strategies on HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022\u20132030","author":"World Health Organization","year":"2022"},{"key":"e_1_2_11_24_1","volume-title":"Interim Guidance for Country Validation of Viral Hepatitis Elimination","author":"World Health Organization","year":"2021"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.09.010"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.031"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.035"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29320"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"e_1_2_11_31_1","first-page":"85","article-title":"\u00c9tude comparative de la fr\u00e9quence des h\u00e9patites B et C chez les personnes nouvellement diagnostiqu\u00e9es pour carcinome h\u00e9patocellulaire en France m\u00e9tropolitaine et dans les d\u00e9partements et r\u00e9gions d'outre\u2010mer, 2015\u20102019","volume":"3","author":"Mwamba\u2010Kalambayi P.","year":"2022","journal-title":"Bulletin \u00c9pid\u00e9miologique Hebdomadaire"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.12.061"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.09.062"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30246"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.363"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i30.5112"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.18462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.18462","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.18462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:15:48Z","timestamp":1771326948000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.18462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/apt.18462"],"URL":"https:\/\/doi.org\/10.1111\/apt.18462","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"2024-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}